Behçet's syndrome: one year in review 2023

This critical review of studies on Be-hcet's syndrome published during 2022 includes studies on epidemiol-ogy, patients' perspective, pathogen-esis, diagnosis, clinical features and management. Studies on pathogenesis included potential biomarkers mostly related to macrophages, neutrophil and cytokine balance, new GWAS and polymorphism studies, and studies on miRNAs and long non-coding RNAs. Clinical studies showed that applica-tion of pneumococcal vaccine to the prick site increased the sensitivity and specificity of the pathergy test and the prevalence of AA amyloidosis had decreased over the years. Studies on management indicated that more data are needed to understand the effect of apremilast on BS manifestations other than oral ulcers, and new BS manifes-tations may develop during treatment with infliximab. Other biologics and Jak inhibitors might be an option for patients who are refractory to TNF-alpha inhibitors. Moreover, endovascular re-pair of arterial aneurysms might be an alternative to open surgery.